XML 36 R20.htm IDEA: XBRL DOCUMENT
v3.20.2

Interim Financial Statements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Reclassifications | The tables below present the impact of the change on the Company’s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company’s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company’s previously-filed Consolidated Statements of Stockholders’ Equity.
|  | December 31, 2019
Balance Sheet Data: |  | As Previously Reported |  | Adjustments |  | As Revised
Accrued expenses and other current liabilities |  | $ | 1,086.8 |  |  | $ | 124.6 |  |  | $ | 1,211.4 |
Deferred revenue - Sanofi (current) |  | $ | 395.5 |  |  | $ | (85.0) |  |  | $ | 310.5 |
Deferred revenue - other (current) |  | $ | 196.2 |  |  | $ | (124.6) |  |  | $ | 71.6 |
Other liabilities - Sanofi (current) |  | — |  |  | $ | 85.0 |  |  | $ | 85.0 |
Deferred revenue - Sanofi (noncurrent) |  | $ | 509.7 |  |  | $ | (482.0) |  |  | $ | 27.7 |
Deferred revenue - other (noncurrent) |  | $ | 109.3 |  |  | $ | (31.7) |  |  | $ | 77.6 |
Other liabilities - Sanofi (noncurrent) |  | — |  |  | $ | 482.0 |  |  | $ | 482.0 |
Other noncurrent liabilities |  | $ | 286.0 |  |  | $ | 31.7 |  |  | $ | 317.7 |
|  | Three Months Ended September 30, 2019 |  | Nine Months Ended September 30, 2019
Statement of Operations Data: |  | As Previously Reported |  | Adjustments |  | As Revised |  | As Previously Reported |  | Adjustments |  | As Revised
Sanofi collaboration revenue |  | $ | 404.2 |  |  | $ | (229.2) |  |  | $ | 175.0 |  |  | $ | 999.7 |  |  | $ | (766.9) |  |  | $ | 232.8 |
Bayer collaboration revenue |  | $ | 302.8 |  |  | $ | (9.2) |  |  | $ | 293.6 |  |  | $ | 868.0 |  |  | $ | (33.2) |  |  | $ | 834.8 |
Other revenue |  | $ | 103.1 |  |  | $ | (66.3) |  |  | $ | 36.8 |  |  | $ | 278.2 |  |  | $ | (199.7) |  |  | $ | 78.5 |
Total revenues |  | $ | 2,048.4 |  |  | $ | (304.7) |  |  | $ | 1,743.7 |  |  | $ | 5,693.9 |  |  | $ | (999.8) |  |  | $ | 4,694.1 |
Research and development |  | $ | 663.4 |  |  | $ | (137.4) |  |  | $ | 526.0 |  |  | $ | 2,353.5 |  |  | $ | (455.9) |  |  | $ | 1,897.6 |
Selling, general, and administrative |  | $ | 419.9 |  |  | $ | (115.5) |  |  | $ | 304.4 |  |  | $ | 1,248.0 |  |  | $ | (357.9) |  |  | $ | 890.1 |
Cost of collaboration and contract manufacturing(1) |  | $ | 110.7 |  |  | $ | (1.1) |  |  | $ | 109.6 |  |  | $ | 304.5 |  |  | $ | (14.9) |  |  | $ | 289.6 |
Other operating (income) expense, net |  | — |  |  | $ | (50.7) |  |  | $ | (50.7) |  |  | — |  |  | $ | (171.1) |  |  | $ | (171.1) |
Total operating expenses |  | $ | 1,309.9 |  |  | $ | (304.7) |  |  | $ | 1,005.2 |  |  | $ | 4,159.8 |  |  | $ | (999.8) |  |  | $ | 3,160.0 |
(1) In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.
|  | Nine Months Ended September 30, 2019
Cash Flows Data: |  | As Previously Reported |  | Adjustments |  | As Revised
Cash flows from operating activities: |  |  |  |  |  |
Increase in deferred revenue |  | $ | 375.8 |  |  | $ | (209.0) |  |  | $ | 166.8 |
Increase in accounts payable, accrued expenses, and other liabilities |  | $ | 119.9 |  |  | $ | 209.0 |  |  | $ | 328.9 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration